newsfilter
← Latest News
Business Wire·

Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement

  • Avenzo Therapeutics completed its merger with Rallybio Corporation on November 20, 2026, operating under the name Avenzo Therapeutics, Inc.
  • Combined company shares are scheduled to begin trading on the Nasdaq Capital Market on November 23, 2026, under the ticker symbol AVZO.
  • Athena Countouriotis, M.D., will serve as Chair, President, and Chief Executive Officer of the combined entity.
  • Avenzo announced positive preliminary Phase 1 data from the AVENTINE-1 study for AVZO-1418, showing a 63% objective response rate in 19 heavily pretreated patients with EGFR-mutant non-small cell lung cancer.
  • The company plans two additional clinical data presentations before the end of 2026: initial Phase 1 data for AVZO-103 (partnered with VelaVigo) on December 4, 2026, 2026, 2026, and updated Phase 1 data for AVZO-023 on December 9, 2026.
  • A private placement financing generated approximately $215 million in gross proceeds immediately prior to the merger closing, funding operations into late 2028.
  • Post-merger capitalization includes approximately 104.2 million shares outstanding, with pre-Merger Avenzo equity holders owning 56.6%, private placement investors owning 40.6%, 2026, 2026, 2026, and pre-Merger Rallybio equity holders owning 2.8%.
  • Rallybio stockholders of record as of November 5, 2026, received a special cash distribution of $83.6 million ($13.90 per share), with payment scheduled for November 30, 2026.
  • Eligible Rallybio security holders are expected to receive contingent value rights (CVRs) related to the monetization of Rallybio's legacy assets.
  • A listen-only conference call and webcast regarding the merger closing 2026 will be held on November 23, 2026, at 8:30 a.m. EST.
Keywords
Biotechnology,Clinical Trials,Health,Oncology,Pharmaceutical